Pfizer is mentioned as a peer in the drug space, with Eli Lilly outperforming it in R&D spending and results over the past decade.
Source Post
Eli Lilly Might Be the Next Stock I Buy | LLY Stock Analysis
Sep 26, 2026
The creator analyzes Eli Lilly (LLY) and believes it might be a stock to buy. The company has gained significant market share in oral weight-loss treatments, with its drug "Zepbound" showing direct medical cost savings. Eli Lilly's revenue has grown substantially, and its operating margins have reached record highs. The creator highlights the company's strong R&D investment and its ability to develop new treatments, suggesting the stock is undervalued at a forward P/E of 24.
Linked Mentions
Tickers discussed in this post
Nvidia is mentioned as an example of a company that experienced a boom similar to the AI boom, drawing a parallel to Eli Lilly's weight-loss drug boom.
Novo Nordisk is mentioned as a competitor in the GLP-1 drug market, with Eli Lilly outperforming it in R&D spending and results over the past decade.
Eli Lilly's stock is potentially undervalued at a forward P/E of 24, making it a buy opportunity.
Linked Signals
Tracked calls opened from this post
LLYbuy opened Sep 26, 2026
+6.22%